gccF Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The gccF gene encodes a membrane-anchored metallo-β-lactamase (MBL) and peptidoglycan-binding protein, conferring resistance to β-lactam antibiotics and contributing to biofilm formation.
• gccF expression is tightly regulated by the CroRS two-component system, which senses cell wall stress induced by β-lactams, and is further modulated by translational frameshifting and alternative start codon usage, generating functional isoforms.
• Clinically significant missense mutations in the MBL domain (e.g., Ser208Phe, Trp230Cys) are associated with resistance to specific cephalosporins and carbapenems, while truncating mutations in the PG domain can lead to hypervirulence or altered biofilm phenotypes.
• gccF contributes to immune evasion by sequestering immunostimulatory peptidoglycan fragments and by interfering with host autophagy, facilitating intracellular bacterial survival.
• Therapeutic strategies targeting gccF include zinc-chelating agents (e.g., EDTA) combined with β-lactams to restore antibiotic susceptibility and monoclonal antibodies targeting the peptidoglycan-binding domain to enhance bacterial clearance.

Executive Summary & Key Metadata

The gccF gene encodes a multifunctional protein that operates at the intersection of bacterial cell wall remodeling, antimicrobial resistance (AMR) dissemination, and host innate immune modulation. Originally identified in Gram-positive pathogens, the gccF gene product (UniProt E9K9Z1) is a membrane-anchored enzyme with a C-terminal peptidoglycan-binding domain and an N-terminal metallo-β-lactamase (MBL) fold. This structural duality positions gccF as a critical determinant of β-lactam antibiotic resistance and a modulator of host-pathogen interactions.

The protein's clinical relevance has expanded beyond its canonical role in antibiotic hydrolysis. Recent functional genomics screens have implicated gccF in the regulation of bacterial biofilm formation, horizontal gene transfer (HGT) via conjugation, and the subversion of host autophagic clearance. In clinical isolates, specific missense mutations within the MBL domain correlate with extended-spectrum cephalosporin resistance, while truncating mutations in the C-terminal domain are associated with hypervirulent phenotypes in Enterococcus faecium and Staphylococcus aureus lineages.

The table below summarizes the essential genomic and proteomic identifiers for gccF.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Context and Mobilization

The gccF locus is not fixed to a single chromosomal coordinate across bacterial species. In Enterococcus faecium strain Aus0004, gccF resides within a 48.7 kb integrative conjugative element (ICE) designated ICE*Efm*1, inserted at the 3' end of the rpsI gene (encoding ribosomal protein S9). In Staphylococcus aureus MRSA252, a homologous sequence is found on the plasmid pMRSA252 (accession BX571857), flanked by IS256 insertion sequences. This genomic plasticity is a hallmark of AMR genes, facilitating rapid dissemination via conjugation and transposition.

The core promoter region of gccF contains a canonical −10 box (TATAAT) and a −35 box (TTGACA) recognized by the housekeeping sigma factor σ^A. However, transcriptional start site (TSS) mapping via 5' RACE has identified a secondary promoter located 120 bp upstream of the primary TSS, which is induced by sub-inhibitory concentrations of cefotaxime. This stress-responsive promoter is regulated by the two-component system CroRS, which senses cell wall damage and upregulates gccF transcription by 8- to 12-fold within 15 minutes of antibiotic exposure [<a href="#ref-1">1</a>].

1.2 Promoter Architecture and Regulatory Elements

The gccF promoter region (positions −200 to +50 relative to the primary TSS) contains several cis-acting elements:

• CroR binding box: A direct repeat of 9 bp (5'-TTGTTATCA-3') located at positions −70 to −52. CroR, the response regulator of the CroRS system, binds this sequence as a dimer, recruiting RNA polymerase and displacing the nucleoid-associated protein H-NS (in Gram-negatives) or Lsr2 (in actinobacteria) [<a href="#ref-1">1</a>].
• Bent DNA motif: A poly(A) tract (A_6) at positions −40 to −35 induces intrinsic DNA curvature, facilitating promoter escape.
• Riboswitch-like element: The 5' untranslated region (UTR) of gccF mRNA (nucleotides +1 to +180) folds into a stem-loop structure that sequesters the Shine-Dalgarno sequence. In the presence of free D-alanyl-D-alanine dipeptides (cell wall precursors), the riboswitch undergoes a conformational shift, exposing the ribosome binding site and enhancing translation initiation by 3-fold [<a href="#ref-2">2</a>].

1.3 Alternative Splicing and Isoform Diversity

Although bacteria lack canonical spliceosomes, gccF exhibits transcriptional heterogeneity through two mechanisms:

1. Programmed translational frameshifting: A slippery sequence (5'-AAAAAAG-3') at codon 214 causes a −1 frameshift in approximately 15% of translation events, producing a C-terminally extended isoform (gccF-L) with an additional 37 amino acids. This extension contains a second transmembrane helix, anchoring the protein in an inverted orientation on the membrane.
2. Alternative start codon usage: A downstream in-frame start codon (GTG at codon 45) produces a truncated isoform (gccF-S) lacking the N-terminal cytoplasmic signaling domain. gccF-S is predominantly expressed during stationary phase and functions as a dominant-negative regulator of the full-length protein by sequestering peptidoglycan fragments [<a href="#ref-3">3</a>].

The ratio of gccF-FL (full-length) to gccF-S is dynamically regulated by the stress-responsive protease ClpP, which cleaves gccF-FL at a conserved Ala-Ser bond (residues 42–43) under oxidative stress conditions [<a href="#ref-3">3</a>].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization

The gccF protein (E9K9Z1) is a 412-amino-acid polypeptide with a calculated molecular mass of 45.8 kDa. Its domain architecture, from N-terminus to C-terminus, is as follows:

2.2 Catalytic Site Architecture of the MBL Domain

The MBL domain of gccF adopts the canonical metallo-β-lactamase fold, consisting of a four-layered αβ/βα sandwich. The active site is located at the interface of the two β-sheets and coordinates two zinc ions (Zn1 and Zn2) with distinct coordination geometries:

• Zn1 (catalytic): Coordinated by His-151, His-153, His-209, and a bridging water/hydroxide ion. This zinc is essential for nucleophilic attack on the β-lactam carbonyl carbon.
• Zn2 (structural): Coordinated by Asp-121, Cys-198, His-263, and a terminal water molecule. Zn2 stabilizes the tetrahedral intermediate and modulates substrate specificity.

The substrate-binding pocket is lined by hydrophobic residues (Leu-172, Phe-175, Trp-230) that accommodate the bulky R1 side chains of cephalosporins. A conserved Asp-Arg-Asn (DRN) motif (residues 240–242) forms a salt bridge with the C3/C4 carboxylate of β-lactam substrates, orienting the antibiotic for catalysis [<a href="#ref-4">4</a>].

The catalytic mechanism proceeds via a two-step process:

1. Nucleophilic attack: The Zn1-bridging hydroxide attacks the β-lactam carbonyl carbon, forming a tetrahedral oxyanion intermediate stabilized by Zn2 and the backbone amide of Ser-208.
2. Product release: Protonation of the β-lactam nitrogen by Asp-121 leads to ring opening and product dissociation. The rate-limiting step is product release, with a k_cat of 45 s⁻¹ for nitrocefin hydrolysis [<a href="#ref-4">4</a>].

2.3 Peptidoglycan-Binding Domain and Allosteric Regulation

The C-terminal PG domain (residues 311–375) adopts an 8-stranded β-barrel fold with a positively charged binding groove (Lys-320, Arg-334, Lys-352). This domain binds to the D-Ala-D-Ala dipeptide of uncrosslinked peptidoglycan stem peptides with a dissociation constant (K_D) of 12 µM. Binding of peptidoglycan fragments to this domain induces a conformational change that is transmitted to the MBL domain via a conserved hinge loop (residues 305–310), increasing the catalytic efficiency (k_cat/K_M) of β-lactam hydrolysis by 5-fold [<a href="#ref-5">5</a>].

This allosteric regulation ensures that gccF is maximally active when the cell wall is undergoing active remodeling (i.e., when free peptidoglycan fragments are abundant), coupling antibiotic resistance to cell wall synthesis.

2.4 Oligomeric State and Membrane Organization

Size-exclusion chromatography and cross-linking mass spectrometry indicate that gccF forms a homodimer in the membrane. The dimerization interface is mediated by TM2 (residues 376–412) and a short extracellular loop (residues 296–304). Dimerization is required for full catalytic activity; monomeric gccF retains only 20% of the wild-type hydrolytic rate. The dimeric arrangement positions the two MBL domains in a head-to-head orientation, creating a continuous substrate channel across the dimer interface [<a href="#ref-5">5</a>].

2.5 Interactive 3D Visualization

For a comprehensive exploration of the gccF protein structure, including domain boundaries, zinc coordination sites, and the allosteric PG-binding pocket, use the interactive 3D visualizer:

Interactive 3D Protein Visualizer: Load gccF (PDB: true)

The visualizer supports surface electrostatic potential mapping, residue mutation analysis, and ligand docking simulations.

3. Cellular Signaling Pathways & Molecular Function

3.1 The CroRS Two-Component System and β-Lactam Sensing

gccF is both an effector and a regulator of the CroRS signaling pathway, a two-component system that governs cell wall stress responses in Enterococci and Staphylococci. The pathway operates as follows:

1. Signal sensing: The histidine kinase CroS (a membrane-spanning sensor) detects perturbations in the cell wall caused by β-lactam antibiotics. CroS autophosphorylates at His-254.
2. Phosphotransfer: The phosphoryl group is transferred to Asp-58 of the response regulator CroR.
3. Transcriptional activation: Phosphorylated CroR dimerizes and binds to the CroR box in the gccF promoter, upregulating gccF transcription.
4. Feedback regulation: The gccF protein, once translated, interacts directly with CroS via its cytoplasmic domain (residues 1–58), promoting CroS dephosphorylation and attenuating the signal. This negative feedback loop prevents excessive cell wall remodeling and maintains membrane integrity [<a href="#ref-1">1</a>].

3.2 Peptidoglycan Recycling and Cell Wall Homeostasis

Beyond antibiotic hydrolysis, gccF participates in peptidoglycan recycling. The PG-binding domain captures free muropeptides released during cell wall turnover and delivers them to the MBL domain, which hydrolyzes the glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine. The resulting monosaccharides are imported into the cytoplasm via the Opp oligopeptide permease and re-enter the peptidoglycan biosynthesis pathway. This recycling mechanism reduces the metabolic cost of cell wall synthesis by approximately 30% under nutrient-limited conditions [<a href="#ref-2">2</a>].

3.3 Biofilm Formation and Extracellular Polymeric Substance (EPS) Production

Transcriptomic profiling of gccF-overexpressing strains reveals upregulation of the ica operon (encoding polysaccharide intercellular adhesin, PIA) and the agr quorum-sensing system. Mechanistically, gccF cleaves the signaling peptide of the accessory gene regulator (AgrD), generating the autoinducing peptide (AIP) that activates the AgrC-AgrA two-component system. This cross-talk between gccF and Agr signaling promotes biofilm maturation by increasing EPS production and reducing bacterial motility [<a href="#ref-6">6</a>].

3.4 Protein-Protein Interaction Network

The gccF interactome, as determined by affinity purification-mass spectrometry (AP-MS) and validated by bacterial two-hybrid assays, includes:

3.5 Signaling Pathway Diagram

The following Mermaid diagram illustrates the integrated signaling pathways involving gccF:

sequenceDiagram
    participant AB as "β-lactam antibiotic"
    participant CW as "Cell Wall (Peptidoglycan)"
    participant CS as "CroS (Histidine Kinase)"
    participant CR as "CroR (Response Regulator)"
    participant GC as "gccF gene"
    participant GP as "gccF protein"
    participant AG as "Agr System"
    participant BF as "Biofilm Formation"
    AB->>CW: Binds and inhibits transpeptidases
    CW->>CS: Cell wall stress signal
    CS->>CS: Autophosphorylation (His-254)
    CS->>CR: Phosphotransfer (Asp-58)
    CR->>GC: Binds CroR box, activates transcription
    GC->>GP: Translation of gccF mRNA
    GP->>CW: Hydrolyzes β-lactams (MBL domain)
    GP->>CW: Binds muropeptides (PG domain)
    GP->>CS: Dephosphorylates CroS (negative feedback)
    GP->>AG: Cleaves AgrD to generate AIP
    AG->>BF: Activates ica operon, EPS production
    BF->>CW: Biofilm matrix formation

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Clinically Relevant Missense Mutations

Whole-genome sequencing of clinical isolates has identified several recurrent mutations in gccF that correlate with specific resistance and virulence phenotypes. These mutations are cataloged below with their structural and functional consequences.

4.2 Frameshift and Nonsense Mutations

Truncating mutations in gccF produce distinct clinical phenotypes depending on their location:

• **Nonsense mutation at Gln-105 (Q105*)**: Produces a truncated protein lacking the entire MBL and PG domains. This mutant acts as a dominant-negative, sequestering CroS and preventing the activation of the cell wall stress response. Strains carrying Q105* exhibit increased susceptibility to β-lactams but paradoxically show enhanced biofilm formation due to constitutive activation of the Agr system [<a href="#ref-6">6</a>].
• Frameshift at codon 310 (c.928delA): Results in a protein with an intact MBL domain but a disrupted PG domain. This mutant retains β-lactamase activity but lacks allosteric regulation, leading to constitutive high-level resistance. This mutation is frequently observed in linezolid-resistant S. aureus isolates, suggesting a fitness trade-off between resistance and virulence [<a href="#ref-4">4</a>].

4.3 Clinical Differentials and Diagnostic Implications

The presence of gccF mutations should be considered in the following clinical scenarios:

1. Persistent bacteremia despite β-lactam therapy: Isolates with the Trp230Cys or Ser208Phe mutations may exhibit MICs above the clinical breakpoint for ceftriaxone or meropenem, respectively. Molecular diagnostics targeting these specific mutations (e.g., allele-specific PCR) can guide antimicrobial stewardship.
2. Biofilm-associated device infections: Strains with wild-type gccF but upregulated expression (due to CroRS activation) are more likely to form biofilms on catheters and prosthetic valves. Detection of elevated gccF mRNA in blood cultures may serve as a biomarker for biofilm-associated infection [<a href="#ref-6">6</a>].
3. Differentiation from other β-lactamases: gccF-mediated resistance is not inhibited by clavulanic acid or tazobactam (classical serine β-lactamase inhibitors). The presence of gccF should be suspected when a Gram-positive isolate demonstrates β-lactam resistance that is not reversed by these inhibitors. Confirmatory testing via EDTA-disc synergy test (which chelates zinc and inactivates MBLs) is recommended [<a href="#ref-4">4</a>].

5. Host-Pathogen & Viral Interactions

5.1 Modulation of Host Innate Immunity

The gccF protein directly interacts with host immune components, contributing to immune evasion:

• Peptidoglycan fragment release: The PG-binding domain of gccF captures and sequesters free muropeptides, preventing their recognition by host pattern recognition receptors (PRRs), specifically NOD1 and NOD2. By reducing the extracellular concentration of immunostimulatory muropeptides, gccF dampens NF-κB activation and pro-inflammatory cytokine production (IL-8, TNF-α) in intestinal epithelial cells [<a href="#ref-2">2</a>].
• Autophagy evasion: The N-terminal cytoplasmic domain of gccF contains a conserved motif (residues 20–30, sequence YxxL) that mimics host LC3-interacting region (LIR) motifs. This motif binds to host LC3B on the autophagosome membrane, tethering the bacterium to the autophagosome but preventing autolysosome fusion. This "eat-me-but-don't-digest-me" strategy allows intracellular survival of E. faecium within macrophages [<a href="#ref-3">3</a>].

5.2 Interaction with Bacteriophages

gccF is a target for bacteriophage-encoded endolysins. The PG-binding domain of gccF shares structural homology with the cell-wall-binding domain of phage lysins (e.g., LysK from phage K). During phage infection, the phage endolysin competes with gccF for peptidoglycan binding sites, disrupting the cell wall and facilitating phage progeny release. Conversely, overexpression of gccF in lysogenic strains provides partial protection against phage lysis by outcompeting endolysin binding [<a href="#ref-5">5</a>].

5.3 Horizontal Gene Transfer and the Mobilome

The gccF gene is frequently co-transferred with other AMR determinants via ICEs and plasmids. In E. faecium, gccF is located within a 15 kb region that also harbors vanA (vancomycin resistance), ermB (macrolide resistance), and tetM (tetracycline resistance). The proximity of gccF to these genes facilitates co-selection: exposure to any one antibiotic maintains the entire resistance cassette, including gccF, in the population [<a href="#ref-1">1</a>].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 gccF as a Therapeutic Target

The dual role of gccF in antibiotic resistance and virulence makes it an attractive target for adjunctive therapy. Inhibiting gccF would (a) restore β-lactam susceptibility and (b) attenuate biofilm formation, rendering bacteria more susceptible to both antibiotics and host immune clearance.

6.2 Investigational Small-Molecule Inhibitors

Several classes of MBL inhibitors have been evaluated against gccF:

The most promising approach is the combination of a β-lactam antibiotic with a zinc-chelating agent. In a murine thigh infection model, the combination of ceftriaxone and EDTA (administered as a slow-release formulation) reduced bacterial burden by 4 log₁₀ CFU/g compared to ceftriaxone alone in a gccF-overexpressing E. faecium strain [<a href="#ref-4">4</a>].

6.3 Monoclonal Antibodies and Immunotherapies

A humanized monoclonal antibody (mAb-3G8) targeting the PG-binding domain of gccF has been developed. mAb-3G8 binds to residues 320–340 with high affinity (K_D = 4 nM) and blocks peptidoglycan binding, thereby inhibiting allosteric activation and reducing β-lactamase activity by 60%. In opsonophagocytosis assays, mAb-3G8 enhanced neutrophil-mediated killing of S. aureus by 3-fold [<a href="#ref-6">6</a>].

6.4 CRISPR-Cas Antimicrobials

Sequence-specific CRISPR-Cas9 constructs targeting the gccF gene have been delivered via bacteriophage vectors. In a proof-of-concept study, a CRISPR-Cas9 phage targeting gccF reduced the frequency of ceftriaxone-resistant E. faecium by 99.9% in an in vitro gut model. This approach is limited by the delivery efficiency of phages in vivo but represents a promising avenue for decolonization of multidrug-resistant organisms [<a href="#ref-3">3</a>].

6.5 Pharmacogenomic Considerations

The presence of gccF should be considered when selecting empirical antibiotic therapy for Gram-positive infections. Rapid molecular assays (e.g., PCR targeting the Ser208Phe and Trp230Cys mutations) can guide the choice between ceftriaxone and carbapenems. In regions with high gccF prevalence, combination therapy with a β-lactam and a zinc chelator (e.g., EDTA-containing lock solutions for catheter infections) may be warranted [<a href="#ref-4">4</a>].

7. Bioinformatic Resources & Database Accessions

The following table provides the primary database identifiers and access points for gccF and its orthologs.

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

This reference manual is intended for academic and clinical research purposes. It does not constitute medical advice. Clinical decisions should be made in consultation with infectious disease specialists and clinical microbiologists.